SecBot SecBot
8-K ·Filed Apr 27, 2026

PAHC

PHIBRO ANIMAL HEALTH CORP
BEARISH
Impact 5/10
Horizonweeks Processed6mo ago SEC0001104659-26-049485
8-K context-dependent: Items 7.01
Actionable Insight ▼ Bearish

Monitor May 7, 2026 earnings call for updated guidance on Brazil exposure and therapeutic registration progress. Assess whether new registrations materialize before the ban takes effect, as failure could materially impact future revenue.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$54.29
T+0 close · Apr 27, 2026 · via day close
Latest settled
−37.30%
T+60 · $34.04
Vs SPY
−41.29%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $54.29entry
  2. T+1 · 7mo ago −1.11%α −1.10% · $53.69
  3. T+5 · 7mo ago +0.72%α −0.97% · $54.68
  4. T+20 · 6mo ago −37.96%α −43.43% · $33.68
  5. T+60 · 4mo ago −37.30%α −41.29% · $34.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phibro Animal Health disclosed a Brazilian regulatory ban on antimicrobial growth promoters including its virginiamycin and bacitracin products, effective after a 180-day transition period. The company expects limited FY2026 impact and is pursuing therapeutic registrations to mitigate long-term effects.

Key Facts

  • Brazilian MAPA Ordinance No. 1617 prohibits use of virginiamycin and bacitracin as growth promoters effective 180 days from April 27, 2026.
  • During transition period, sales and use under current labels continue.
  • Phibro expects limited impact on fiscal year 2026 results.
  • New registrations for therapeutic use of virginiamycin in cattle and broiler chickens are in final MAPA review and expected during transition.
  • Bacitracin already carries therapeutic claims in Brazil.
  • PhibroVet digital platform will facilitate veterinary prescriptions post-ban.

Financial Impact

Limited impact on FY2026 results; no specific dollar amounts provided.

revenue from virginiamycin and bacitracin sales in Brazil

Risk Factors

  • Therapeutic registrations may not be approved before the ban takes effect, leading to revenue loss in Brazil.
  • Other markets could adopt similar restrictions on antimicrobial growth promoters.
  • Uncertainty about the magnitude of long-term financial impact beyond FY2026.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
11% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-049485
Document: tm2612861d1_ex99-1.htm0001104659-26-049485
Document: 0001104659-26-049485-index-headers.html0001104659-26-049485
Document: 0001104659-26-049485-index.html0001104659-26-049485
Document: 0001104659-26-049485.txt0001104659-26-049485

US Market Status

Market Closed · Opens in 5h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026